Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.51B | 1.56B | 1.66B | 1.11B | 1.17B | 1.04B |
Gross Profit | 1.33B | 1.31B | 1.41B | 893.73M | 976.43M | 860.44M |
EBITDA | 447.71M | 494.86M | 519.48M | 59.77M | 177.60M | -6.02M |
Net Income | 352.71M | 367.07M | 355.76M | -158.27M | -48.17M | -110.86M |
Balance Sheet | ||||||
Total Assets | 2.08B | 2.06B | 2.14B | 1.96B | 2.02B | 1.95B |
Cash, Cash Equivalents and Short-Term Investments | 399.81M | 751.67M | 773.49M | 740.08M | 765.74M | 659.81M |
Total Debt | 74.10M | 75.54M | 372.19M | 293.27M | 295.80M | 274.96M |
Total Liabilities | 570.39M | 590.59M | 933.54M | 920.23M | 911.90M | 882.75M |
Stockholders Equity | 1.51B | 1.46B | 1.20B | 1.04B | 1.11B | 1.07B |
Cash Flow | ||||||
Free Cash Flow | 481.57M | 405.64M | 353.31M | -17.21M | 72.69M | 40.62M |
Operating Cash Flow | 516.83M | 439.12M | 401.35M | 21.04M | 101.72M | 82.84M |
Investing Cash Flow | -62.26M | -111.31M | 53.36M | -64.54M | -66.20M | -11.48M |
Financing Cash Flow | -475.52M | -494.14M | -289.71M | -1.57M | 29.07M | -2.17M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $4.33B | 36.12 | 13.90% | ― | 247.53% | 118.34% | |
73 Outperform | $4.37B | 12.63 | 25.71% | ― | -12.31% | -17.53% | |
60 Neutral | HK$17.07B | 6.10 | -7.44% | 2.88% | 11.55% | -28.15% | |
58 Neutral | $6.75B | ― | -118.53% | ― | -7.65% | -11.81% | |
54 Neutral | $5.24B | ― | -282.16% | ― | 72.16% | 9.65% | |
47 Neutral | $1.27B | 19.61 | -23.61% | ― | 59.15% | -1881.09% |
On July 21, 2025, Alkermes announced positive topline results from its Vibrance-1 phase 2 study, which evaluated the safety and efficacy of alixorexton in patients with narcolepsy type 1. The study demonstrated that alixorexton significantly improved wakefulness and patient-reported outcomes related to disease severity, fatigue, and cognition compared to placebo. These results support the advancement of alixorexton to phase 3 development, highlighting its potential as a transformative treatment in the narcolepsy market.
The most recent analyst rating on (ALKS) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
On May 21, 2025, Alkermes plc held its annual general meeting where shareholders approved amendments to the 2018 Stock Option and Incentive Plan, increasing the number of authorized shares by 4,250,000. Additionally, shareholders elected directors, approved executive compensation, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and renewed the Board’s authority to allot and issue shares under Irish law, reflecting strong shareholder support for the company’s strategic initiatives.
The most recent analyst rating on (ALKS) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.